STUDresearch · Peptide
P21
Also known as
P021 · Peptide 021 · Peptide 21 · P21 peptide · P021 peptide · CNTF-derived peptide P21 · CNTF small-molecule peptide mimetic P021 · Ac-DGGLAG-NH2 (adamantylated form) · Ac-DGGL A G-NH2 · GLXC-21260 (catalog-style ID in some listings) · CAS 1246751-68-7 (common registry listing)
Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.
Peptide
Some talk
Systemic
Nasal / SubQ / Oral
Cognitive / nootropic peptides
Brain-focused research peptide — nasal, SubQ and oral reports do not establish targeted human brain delivery.
What people say
P21/P021 is an adamantylated CNTF-derived research peptide discussed for memory and neuroplasticity. It is not the p21 cell-cycle protein or an isolated Cerebrolysin ingredient; its efficacy evidence is chiefly rodent research.
Doses people talk about
Daily totals, individual administrations and routes differ across accounts. Higher multi-mg nasal outliers, including a preserved 12 mg experimental outlier, are not a recommended range. Oral animal studies do not validate human capsule bioavailability or a human dose.
How it may feel
Reports include clearer recall and calmer mood over weeks, little response, and fading benefit. A two-day SubQ account described panic followed by stimulation; nasal reports also include severe, unverified vision warnings. Stacks and uncertain product identity limit attribution.
Inspected nasal diary125–250 mcg daily
Reported clearer thinking and recall at about 3 weeks, then diminishing effectiveness; the same author planned a break, with no verified restart result.
Inspected SubQ adverse account600 mcg SubQ
A two-day report described about an hour of panic followed by stimulation; usual Semax and a subsequent switch to Selank confound the experience.
Repeated SubQ chart~100–300 mcg/day
Usually once daily in the preserved education/vendor charts; other lower-start discussions cite 100–250 mcg and 250–500 mcg.
Other SubQ reports/charts200–400 mcg per injection
The underlying notes also retain 100–400 mcg reports and 100–500 mcg/day secondary schedules. These are overlapping conventions, not tested dose tiers.
Broader daily discussion500 mcg–1 mg daily; broader 100 mcg–2 mg/day
The broader figure spans nasal and SubQ write-ups and cannot be treated as one route-specific standard.
Other nasal discussion0.5–1 mg/day
More aggressive reports reach multi-mg/day; the preserved record describes an “RDA ~1 mg then 3–4 mg after months” account and experimental days up to ~12 mg. These are outliers, not consensus or validated safe amounts.
Animal injection context~0.1 mg/kg daily; broader 0.1–1.0 mg/kg daily
SC/IP rodent efficacy ranges, including a reported 0.5–1.0 mg/kg plateau, are not human amounts or human PK.
Half-life & effect duration
- Half-life in the body
- Pooled plasma stability testAbout 180–200 minutes — roughly 3 hours
- Felt duration people report
- One nasal accountBenefit around 3 weeks, later fading
- One injected accountAbout 1 hour of panic, followed by stimulation
- Other accountsClearer recall or no clear effect
Cycles people discuss
Community calendars range from 5–14 days or 1–4 weeks to 4–6, 4–8 or 8–12 weeks; some describe 2–3 runs yearly. Fading feel, burnout and safety uncertainty drive breaks. Multi-month rodent courses do not validate those human schedules.
Timing
Morning use is common in the notes because late or higher doses are linked to sleep disruption. Daily or split patterns are community conventions, not intervals validated by the plasma-stability assay.
Stacks
Semax, Selank, Dihexa and other cognitive stacks recur in discussion. P21/PE-22-28 co-use also has an anger/instability report; combined use makes attribution particularly difficult.
Watch for
Stop patterns (anecdote only): Stop for vision changes, severe mood instability, progressive hair loss that is unacceptable, or persistent headache/irritability — personal thresholds, not protocol rules.
Tap a line to jump into the full notes. Research only — may be wrong.
Timing context & sources
Half-life in the body
A human parent elimination half-life is not established by the reviewed P021 evidence.
The patent reports 50% remaining at 180–200 minutes in pooled human plasma/PBS in vitro. It separately describes mouse IP brain sampling; neither result measures human nasal, oral or SubQ elimination.
An in-vitro degradation result excludes whole-body distribution, absorption and clearance. Vendor repetition of >3 hours and rodent CNS effects cannot supply a human PK range.
- Iqbal & Grundke-Iqbal — Neurotrophic peptides for the treatment of tauopathies (US20140357572A1) (opens in a new tab)Example 2, paragraphs describing P021 structure and pooled-plasma stability; HTML text around lines 1808–1816 / patent paragraphs 0122–0125. HPLC assay: 50% remaining at 180–200 min; separate mouse IP brain sampling at 10/30 min.Primary inventor disclosure, not a human dosing study or independent PK replication. Human pooled plasma was used in vitro; brain exposure was measured in mice. Neither establishes human nasal, oral or SubQ elimination or bioavailability. No patent preparation procedures are projected.
Felt duration people report
Reports range from acute panic/stimulation to clearer recall over weeks, no clear effect, and fading benefit; no consistent per-dose duration is established.
A nasal user specified 125–250 mcg daily, initially reported benefit at about 3 weeks, then later described fading effectiveness. A different 600 mcg SubQ reporter described about an hour of panic followed by stimulation across a two-day account.
Same-author chronology matters: a planned break is not a successful restart. Product, Semax/Selank changes and expectation are confounders. Severe vision allegations are retained as unverified safety reports, not a measured P21 effect rate.
- P21 peptide — nasal diary and later loss-of-effect update (opens in a new tab)Jalex1984 OP: daily nasal use for about 3 weeks; same author reply specifies 125–250 mcg daily; later same-author reply says effectiveness is fading and plans a break (opened text lines 19, 49–55, 110–115).Anonymous unverified product and outcome. The later reply does not establish how much later it was posted or whether restarting succeeded. Deleted comments and collapsed branches were not reconstructed; vendor mention is not endorsement.
- P-21 Experience: 600mcg SC Report — two-day panic/stimulation account (opens in a new tab)nootropics_warrior OP, Day 1/Day 2 sections, 600 mcg SubQ; comment asking for an OP update has no visible response. Separate Rodnick007 reply reports persistent hot-head sensations and prior tinnitus (lines 23–46, 104–117).Two-day uncontrolled account with Semax/Selank change; no OP longer-term result verified. The later hot-head/tinnitus report is a different author, not OP follow-up. Product purity and causality unverified.
- P21 — discussion containing 1 mg nasal fading response and vision warning (opens in a new tab)themission2 reply: 1 mg intranasal became noticeable then less noticeable (lines 120–127); No-Boss5817 later reply alleges retinal injury (129–135).The long mechanistic opening is quoted vendor copy and is not used as primary science. Retinal claim is anonymous and unverified, with no incidence estimate; the detailed legacy retina report remains preserved without pretending this brief reply verifies its clinical tests.
What people say
- Memory / learning (community): Gradual consolidation, study stickiness, or “less fog” over weeks — confounded by sleep, stacks, and expectation; not a caffeine-style onset. forum
- Clarity without stim buzz: Subset report clearer thinking without jitter/crash; others report null or only dream/mood changes. anecdote
- vs Semax (community typology): Cast as slow/structural neurogenesis vs Semax’s more acute BDNF/focus modulation — useful typology, not a head-to-head RCT. forum
- Null / non-responders: Common; purity, dose band, route, cycle length, and “structural not acute” expectations explain most forum debates. forum
- Stack confound: Frequently co-logged with Semax, Selank, Dihexa, cerebrolysin courses, sleep changes, or study load — single-agent credit is weak. forum
- Neurogenesis (animals): Higher dentate gyrus proliferation/maturation markers (BrdU, DCX/NeuN-class readouts) in adult mice after peripheral P021. animal
- Healthy-mouse cognition: Early adamantane-peptide work (Li et al. 2010 class) reported improved learning and short-term / spatial reference memory with increased neurogenesis and synaptic plasticity markers in normal mice. animal
- AD-model cognition: Better maze / object-recognition–class scores and rescue of episodic-type deficits in 3xTg-AD and related models when treatment covers disease-relevant windows. animal
- Tau markers: Chronic oral P021 in 3xTg-AD mice reduced hyperphosphorylated tau / tau pathology with synaptic preservation; aged-rat oral work reported lower brain/CSF total tau with BBB-permeability discussion (Khatoon 2015 class). animal
- Amyloid angle: Attenuation of soluble Aβ generation and trends toward lower plaque load in CA1 reported in some 3xTg-AD treatment windows — model- and timing-dependent. animal
- Synaptic / dendritic structure: Rescued dendritic morphology, spine/synaptic transmission deficits, and higher synaptic proteins (e.g. MAP2, synapsin I, GluR1/AMPA-related, NR1) in disease models. animal
- BDNF / CREB axis: Increased BDNF, phospho-CREB, and neurotrophin-4 talk across multiple Iqbal-lab papers; GSK-3β inhibition via Akt-linked phosphorylation is a recurring tau-protective chain. animal
- Cognitive aging (oral rats): Chronic oral P021 for ~88 days in 22–24-month-old Fisher rats rescued age-associated neurogenesis/plasticity deficits and learning-memory decline with cortical/hippocampal BDNF and synaptic-activity support. animal
- Down syndrome model: Prenatal-to-early-postnatal P021 rescued developmental delay and later AD-like hippocampal memory deficits in Ts65Dn mice with BDNF/pCREB up and GSK-3β down (Kazim 2017 class). animal
- Survival signal (disease model): Kazim 2014 3xTg-AD oral program is often cited for higher survival fraction vs vehicle (vendor/secondary summaries quote vehicle ~41% vs P021 ~87% in that experiment) — animal disease-model mortality, not human lifespan data. animal
- Retinal / AMD-like endpoints (secondary animal): Later same-lab work reported amelioration of age-related macular-degeneration–like retinal pathology in aged rats / 3xTg-AD mice — research endpoint, not a community eye protocol. animal
- vs full CNTF clinical baggage: Small peptide framed as skipping anorexia/cachexia profile of parent CNTF protein. trial
- Oral animal angle: Oral efficacy in disease and aging models is a major differentiator vs peptides that only work injectably in animals — drives non-inject interest even though human oral PK is sparse. animal
Doses people talk about
- Conservative subq band (common research-chem charts): ~100–300 mcg/day subcutaneous once daily — still the most repeated “protocol card” band on several peptide-education sites. forum
- Modal community/vendor daily figure: Roughly 500 mcg–1 mg once daily is the number that circulates most often across 2025–2026 dosing roundups. forum
- Broader cited community range: About 100 mcg–2 mg/day across subq and nasal write-ups. forum
- International Peptide Society–style subq charts (secondary): 100–500 mcg daily for ~4–6 weeks; conservative start 100–250 mcg weeks 1–3, optional rise to 250–500 mcg weeks 4–6 — vendor/secondary guidance, not a regulator protocol. forum
- PeptIQ-style self-report buckets (anonymized logs): Median/most-common injection bucket often lands 200–400 mcg; reports spanning ~100–400 mcg in small samples — selection-biased, not a trial. A separate 600 mcg SubQ report described acute panic followed by stimulation over its first 2 days, with Semax/Selank confounding. anecdote
- Nasal start (forum): ~0.5–1 mg/day common discussion; spray concentration and mg per spray vary wildly by DIY/vendor. A separately inspected nasal diary specified 125–250 mcg daily; early clarity at roughly 3 weeks later faded. forumanecdote
- Nasal / high-end logs: Some escalate to multi-mg/day (e.g. “RDA ~1 mg then 3–4 mg after months,” experimental days to ~12 mg) — outliers, cost-limited, not consensus. anecdote
- Example early subq titration log (NooTopics-style): Day 1 ~500 mcg → day 2 ~750 mcg → day 3 ~1 mg morning; early days often inconclusive. anecdote
- Route-dose mismatch warning: Best animal disease data is often oral/peripheral continuous; community human talk skews subq + nasal at microgram–low-mg — different route and different evidence base. forum
- P6c vs P21: Community notes P6c as related shorter motif without adamantane — not interchangeable with adamantylated P021 on dose or PK folklore. forum
- New-user lower end: ~250–500 mcg (sometimes 100–250 mcg first days) then step within personal range. forum
- Titration culture: Start low several days, only step if tolerated; avoid mega-escalation solely because “neurogenesis needs more.” forum
- Purity / identity flag: Without HPLC/identity testing, labeled mcg may not match contents; recombinant “P21 protein” listings are not the same as the short adamantylated peptide. forum
- Framing: Discussed research / community ranges only — not advice, not prescriptions, not trial-validated human protocols. Gray-market identity and purity make labeled mcg/mg soft. forum
- Rodent oral / diet: Oral chronic programs (aged rats ~88 days; 3xTg-AD disease modification) used oral/dietary delivery; example chow formulation ~60 nmol peptide/g diet (~2.7 g diet/day per mouse in one prenatal program) — research formulation, not a capsule schedule. animal
- Oral animal vs oral human gap: Animal GI stability + oral efficacy drive interest; human oral bioavailability % and effective capsule doses are not established. trial
- No established human dose: Zero human RCTs define a therapeutic or safe dose; every human figure is vendor chart or self-report. trial
- Rodent efficacy anchors (not 1:1 human map): Common effective band 0.1 mg/kg daily SC/IP (plateau often described vs 0.5–1.0 mg/kg); broader published paradigms 0.1–1.0 mg/kg daily for 2–4 weeks (cognition) up to multi-month AD models. animal
- Intranasal animal charts (secondary monographs): ~0.05–0.2 mg/kg once daily for multi-week windows appear in research summaries — not human nasal spray recipes. animal
How it may feel
- Day 1 (stim expectation): Little classic stimulant “on”; logs that expect racetam/caffeine flash often rate it a dud early. An acute counterexample reported 600 mcg SubQ followed within seconds by about an hour of panic, then euphoria/task drive and better sleep; the next day's report included a switch from usual Semax to Selank and continued stimulation. This is a confounded two-day account, not a typical onset. forumanecdote
- Days 1–7: Quiet window for many; vivid dreams or subtle mood/edge notes appear before clear cognitive claims. forum
- Week 1 nasal anecdotes: Some first-notice reports after ~1 mg intranasal (e.g. early Yinherb-style logs) with rapid tolerance of the noticeable edge — not universal. anecdote
- Weeks 1–2: First memory/clarity notes often claimed here, not day one; common first keep-or-stop checkpoint. forum
- Weeks 2–3: Subjective plateau / “burnout” or loss of the early good feeling is a repeated community pattern on continuous daily use. In an inspected nasal diary, Jalex1984 reported clearer reading/recall and calmer mood at about 3 weeks, clarified 125–250 mcg daily, then later said effectiveness was fading and planned a break; no successful restart outcome was visible. forumanecdote
- Weeks 2–4: Reassess window on 1–4 week community blocks; decide whether any consolidation edge is real enough to re-run later. forum
- ~1 month continuous (patience lore): Some secondary guides say full structural effects may lag ~a month — clashes with users who already feel flat by week 2–3. forum
- Research-length continuous (4–8+ weeks): Matches rodent disease-model exposure more than healthy-user comfort; community often abandons continuous before research-length ends. forum
Cycles people discuss
- Community short courses: ~5–14 days on is frequently preferred when continuous use feels flat by week 2–3. forum
- Community 1–4 weeks on + long off: Still common in write-ups that try to balance structural timeline with tolerance talk. forum
- Vendor/secondary 4–6 weeks: Aligns with some “International Peptide Society–style” subq charts then break to assess residual effect. forum
- 4–8 weeks convention (catalog roundups): Morning daily for 4–8 weeks with time off is a circulating convention table figure — still not trial-defined. forum
- Year pattern: A few intermittent runs/year (often cited 2–3) more common than indefinite daily among cautious logs. forum
- Why off: Subjective tolerance/burnout, cost, gray-market source risk, and near-zero long-term human safety data. forum
- Research vs community divergence: Continuous multi-week animal pathology dosing ≠ healthy-user subjective cycle culture; diminishing “feel” may not equal zero biology, but users still cycle. forum
- Avoid open-ended forever-daily (community norm): Especially at multi-mg nasal/subq — where rarer severe anecdotes cluster. forum
- Research continuous blocks: Rodent disease/aging studies often run multi-week to multi-month daily exposure (e.g. 4–8 weeks cognition paradigms; 6–12 months AD-model talk in monographs; ~88-day oral aged-rat block). animal
- Longer secondary charts: 8–12 week cognitive protocols appear on some protocol pages (often nasal 500–1000 mcg framing) — longer than many user comfort reports. forum
Timing
- Dosing logic in community talk: Daily, sometimes split, use is contrasted with weekly depot dosing. The multi-hour in-vitro stability figure does not validate a human coverage window or dosing interval. forum
- Delayed feel vs clearance: Community explanations contrast a presumed hours-long blood clock with multi-week neuron birth/integration and use that story to justify patience or no sensation at Tmax. Neither a human blood-clearance value nor a human neurogenesis timeline is established for P21; some users also report acute effects. forum
- Timing of day: Morning dosing is the community default (sleep disruption / overstimulation anecdotes with late or high doses). forum
- Nasal clearance general peptide note: Nasal mucosal clearance is fast for peptides in general; formulation (vehicle, volume per nostril) dominates practical exposure — P21-specific nasal F% not established. forum
- Plasma stability, not human elimination: Secondary summaries repeat almost ~3 hours of plasma stability and vendor copy says “plasma half-life exceeding 3 hours.” The originating patent describes an in-vitro pooled human-plasma/PBS assay reaching 50% remaining at 180–200 minutes; this is not in-vivo human clearance. lab
- Gastric / gut stability (key oral story): Better than 95% stability in synthetic gastric juice over ~30 minutes; ~100% stable in gut fluid for ~2 hours in widely repeated CNTF-mimetic summaries — basis for oral animal programs. The patent's assay description reports >90% in artificial gastric juice to 30 minutes and >95% in artificial intestinal juice to 2 hours; the higher percentages are secondary retellings, not human oral bioavailability. animallab
- BBB: Peripheral/oral programs report CNS effects and BBB-permeability claims (including adamantane lipophilicity rationale); exact human brain exposure unknown. animal
- Cumulative / structural talk: “Low and slow” plasticity framing rather than acute loading boluses. forum
- No solid human chronobiology or PK: No published human T½, Tmax, F%, or CSF levels for gray-market product. trial
More on what it is
- Why people care: Marketed and discussed as a “structural” neurogenic nootropic — dentate gyrus neurogenesis, BDNF up, synaptic markers — not a day-one stimulant focus pill. forum
- What it is: Synthetic CNTF-region peptide mimetic best known in literature as P021 / Peptide 021 — commonly written P21 in nootropic forums. Core active motif maps to CNTF residues ~148–151 (DGGL class); the research compound is the adamantane-modified, N-acetyl / C-amide form often given as Ac-DGGLAG-NH2 (MW ~578 in papers; adamantylated glycine improves lipophilicity and exopeptidase resistance). Not the cell-cycle protein p21/CDKN1A. trial
- Lab origin: Developed in Khalid Iqbal’s group (New York State Institute for Basic Research) from epitope-mapping work that pared CNTF neurotrophic activity down to a short defined peptide (parent lineage includes the longer 11-mer P6 / Ac-VGDGGLFEKKL-NH2 and truncated P6c without adamantane). trial
- Mechanism talk (proposed): Does not act like full CNTF receptor agonism in the simple sense; papers emphasize competitive LIF signaling inhibition (STAT3/pSTAT3 readout), increased BDNF / TrkB-linked cascades (MAPK, PI3K/Akt), inhibitory GSK-3β phosphorylation, and downstream tau-protective / synaptic-marker effects. Antibody-sequestration / endogenous-CNTF support talk also appears in secondary write-ups. animal
- vs full CNTF: Small peptide framed to cross BBB and avoid classic systemic CNTF liabilities (anorexia, weight loss, antibody formation to full-length protein) seen in older ALS-era CNTF trials. trial
- vs Cerebrolysin: Not “the active fragment extracted from Cerebrolysin.” Cerebrolysin is a complex porcine brain hydrolysate; P021 is a single synthetic molecule inspired by CNTF-region mapping that also informed how people talk about cerebrolysin’s neurotrophic pieces. Animal head-to-heads and marketing sometimes claim P21 > cerebrolysin on selected endpoints — still not clinical equivalence. trial
- Evidence honesty: Multi-year rodent program (aging, 3xTg-AD, sporadic AD-style models, Down-syndrome Ts65Dn, etc.), largely single-lab cluster, internally consistent on neurogenesis/cognition/tau direction — no published human nootropic RCTs, no Phase 1 PK package, not FDA-approved. trial
- Not the same as: Full CNTF, Cerebrolysin, Semax, Dihexa, PE-22-28, Noopept, or any approved cognitive drug. trial
Stacks
- Semax (most common pair): Acute BDNF/focus/verbal edge alongside slower “neurogenic hardware” P21 talk — stack or alternate if overstim/hair/mood issues appear. forum
- Selank: Calm/stress tone when cognitive stacks feel edgy; often with Semax as a triple. forum
- Dihexa: Structural plasticity stack via different pathway (HGF/c-Met vs CNTF/LIF/BDNF) — hard to attribute outcomes; high theoretical growth-pathway caution when both are high. forum
- Cerebrolysin: More compare/alternate (clinic courses vs research-chem daily) than true same-syringe co-stack; some sequence courses. forum
- PE-22-28 (mini-spadin / TREK-1): Sometimes co-logged for mood + structure; at least one community report of severe anger/emotional instability when mixed with P21 — start alone, caution combining. anecdote
- Noopept / racetam-era neighbors: Older nootropic stacks occasionally include P21 as the “neurogenesis” piece. forum
- NAD+ (IV or other): Energy co-factor marketing in wellness cognitive packages — confounds credit. forum
- BPC-157: Occasional “systemic repair + CNS neurogenesis” forum talk without published combo data. forum
- Lifestyle co-factors: Sleep, aerobic/resistance training, and deliberate learning load often share credit for good logs. forum
- Stack hygiene: Add one compound at a time; multi-neurotrophic piles make sides (mood, hair, sleep, dreams) unattributable. forum
- Pinealon: “Protect while you build” framing — pinealon as oxidative/mito neuroprotectant next to P21 neurogenesis talk. forum
Storage notes
- No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
- Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum
Watch for
- Vivid dreams: Among the most common subjective notes; often linked (speculatively) to hippocampal/plasticity activity during sleep. forum
- Mood / emotional sensitivity: Heightened reactivity, irritability, or “rewiring feels” in a subset — more reports when stacked. forum
- Sleep disruption / wired feel: Especially higher doses or evening dosing — drives morning-only convention. forum
- Headache: Occasional community complaint (generic peptide/nootropic pattern). forum
- Hair shedding / thinning: Minority heavy-use anecdotes (including Cerebrolysin-sub reports); mechanism often hand-waved as BDNF/neurotrophic hair-cycle disruption similar to Semax lore — no controlled human rate, no follicle study on P21. anecdote
- Local irritation: Subq injection-site reactions; nasal mucosa burn/irritation with sprays. forum
- Tolerance / diminishing subjective returns: Multi-week continuous use often feels flatter → cycle culture. forum
- Vision / retina red-flag anecdotes (rare but severe): Reddit logs (including NooTopics thread replies) describe lasting visual disturbance after high cumulative intranasal use of gray-market P21 (e.g. multi-month, high total mg from Ceretropic / Cuerpoymente-era sources) — afterimages, glare, halos, blur, accommodation difficulty; one detailed report claimed multi-specialist workup with severely suppressed cone mfERG amplitudes and no clear diagnosis. Users link to CNTF’s known complex retinal biology. Unproven causality, possible confounded product identity, not a measured incidence rate — still treated as a hard stop signal if any vision change appears. anecdote
- PE-22-28 combo caution: Single clear community report of extreme anger/emotional instability when P21 experience was mixed with PE-22-28. anecdote
- Theoretical proliferation caution: Any chronic neurogenesis/growth-factor-pathway agent attracts generic “uncontrolled proliferation / malignancy history” caution in community risk talk — no published P21 cancer signal, still a personal risk conversation. forum
- Source / gray-market risk: Mislabel, underdose, contamination, and wrong molecule (protein vs short peptide) are independent of any rodent safety paper. forum
- Special populations (secondary caution lists): Active malignancy, epilepsy, pregnancy/lactation, and autoimmune disease appear on conservative protocol pages as extra-uncertainty groups — not trial exclusion tables. forum
- Stop patterns (anecdote only): Stop for vision changes, severe mood instability, progressive hair loss that is unacceptable, or persistent headache/irritability — personal thresholds, not protocol rules. forum
- Rodent safety signal (limited): Blanchard-era / related PK-safety characterizations and multi-month oral animal programs report no classic psychostimulant addiction profile and generally favorable observed tolerability — rodent ≠ human long-term safety database. animal
- Immunogenicity theory: Full CNTF and porcine extracts raise antibody concerns in literature/history; P021 is framed as less antigenic, but formal human immunogenicity data are absent. Secondary reviews mention antibody formation as theoretical for tau-targeting peptide classes. trial
- Evidence / honesty caution: Strong-looking rodent package from a largely single lab does not equal proven human cognitive enhancement; enthusiasm outruns human data. trial
Evidence mix
Mostly community / anecdote tags
Full: every bullet (trial + community). Use Scan for a faster bro-science read.